Compare · GUTS vs RMD
GUTS vs RMD
Side-by-side comparison of Fractyl Health Inc. (GUTS) and ResMed Inc. (RMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GUTS and RMD operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- RMD is the larger of the two at $34.07B, about 617.4x GUTS ($55.2M).
- RMD has been more active in the news (9 items in the past 4 weeks vs 6 for GUTS).
- RMD has more recent analyst coverage (25 ratings vs 6 for GUTS).
- Company
- Fractyl Health Inc.
- ResMed Inc.
- Price
- $1.55-62.47%
- $239.08-1.35%
- Market cap
- $55.2M
- $34.07B
- 1M return
- -78.11%
- -
- 1Y return
- -90.81%
- -
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 6
- 9
- Recent ratings
- 6
- 25
ResMed Inc.
ResMed Inc. develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep apnea, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. The company also provides U-Sleep, which enables automated patient coaching through a text, email, or interactive voice phone call; AirView that enables remote monitoring, over-the-air trouble shooting, and changing of device settings; and myAir, a patient engagement application that offers sleep data and a daily score based on their previous night's data, as well as connectivity module and propeller solutions. In addition, it provides business management software and services to out-of-hospital providers, home medical equipment, pharmacy, home infusion, orthotics, and prosthetics; and HEALTHCAREfirst and MatrixCare solutions. The company markets its products to sleep clinics, home healthcare dealers, patients, hospitals, physicians, and third-party payers through a network of distributors and direct sales force in approximately 140 countries. ResMed Inc. was founded in 1989 and is headquartered in San Diego, California.
Latest GUTS
- GUTS UPCOMING DEADLINE: Levi & Korsinsky Alerts Fractyl Health, Inc. Stockholders of Securities Class Action - Contact the Firm
- SEC Form 8-K filed by Fractyl Health Inc.
- Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in Ongoing REMAIN-1 Pivotal Study, With Highly Statistically Significant Reduction in Weight Regain After GLP-1 Discontinuation
- GUTS Shareholder Alert: Fractyl Health, Inc. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
- GUTS DEADLINE: Levi & Korsinsky Reminds Fractyl Health, Inc. Investors of Upcoming Securities Class Action Deadline
- Fractyl Health Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Fractyl Health Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Director Bradley William bought $39,903 worth of shares (64,516 units at $0.62), increasing direct ownership by 76% to 149,138 units (SEC Form 4)
- Fractyl Health Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- Fractyl Health to Participate in Upcoming September Investor Conferences
Latest RMD
- SEC Form 4 filed by ResMed Inc.
- SEC Form DEFA14A filed by ResMed Inc.
- SEC Form DEF 14A filed by ResMed Inc.
- Amendment: SEC Form 4 filed by Chairman and CEO Farrell Michael J.
- Chief Product Officer Leong Justin was granted 6,461 units of ResMed Common Stock, increasing direct ownership by 22% to 35,489 units (SEC Form 4)
- Global General Counsel Rider Michael J was granted 3,230 units of ResMed Common Stock, increasing direct ownership by 34% to 12,718 units (SEC Form 4)
- Chairman and CEO Farrell Michael J. was granted 13,547 units of ResMed Common Stock, increasing direct ownership by 3% to 479,803 units (SEC Form 4)
- Chief Financial Officer Bloomer Aaron was granted 9,072 units of ResMed Common Stock (SEC Form 4)
- Resmed to Report First Quarter Fiscal 2027 Earnings on October 29, 2026
- ResMed upgraded by RBC Capital Mkts with a new price target